Apolipoprotein E mimetic peptide CN-105 improves outcome in a murine model of SAH.

Published

Journal Article

Objective:Subarachnoid haemorrhage (SAH) accounts for 3% of all strokes, and is associated with significant morbidity and mortality. There is growing evidence implicating apolipoprotein E (apoE) in mediating adaptive anti-inflammatory and neuroprotective responses following ischaemic and traumatic brain injury. In the current study, we test the efficacy of a small apoE mimetic peptide, CN-105 in a murine model of SAH. Methods:Mice subjected to SAH received repeated intravenous injections of CN-105 every 12 hours for 3 days, with the first dose given 2 hours after injury. Daily functional outcomes were assessed by rotarod and neurological severity score. Haemorrhage grade and cerebral vascular diameters were measured at 5 days post-SAH. Cerebral microgliosis, neuronal degeneration and survival were analysed at 5 and 35 days post-SAH, respectively. Results:CN-105 reduces histological evidence of inflammation, reduces vasospasm and neuronal injury and is associated with improved long-term behavioural outcomes in a murine model of SAH. Conclusions:Given its favourable pharmacokinetic profile, central nervous system penetration and demonstration of clinical safety, CN-105 represents an attractive therapeutic candidate for treatment of brain injury associated with SAH.

Full Text

Duke Authors

Cited Authors

  • Liu, J; Zhou, G; Kolls, BJ; Tan, Y; Fang, C; Wang, H; Laskowitz, DT

Published Date

  • December 2018

Published In

Volume / Issue

  • 3 / 4

Start / End Page

  • 222 - 230

PubMed ID

  • 30637128

Pubmed Central ID

  • 30637128

Electronic International Standard Serial Number (EISSN)

  • 2059-8696

International Standard Serial Number (ISSN)

  • 2059-8696

Digital Object Identifier (DOI)

  • 10.1136/svn-2018-000152

Language

  • eng